Florida Court Rules for Aveva in Lidocaine Patch Patent Dispute
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Scilex Pharmaceuticals, Inc. v. Aveva Drug Delivery Systems, Inc. |
| Case Number | 0:22-cv-61192 (S.D. Fla.) |
| Court | U.S. District Court for the Southern District of Florida |
| Duration | June 2022 – August 2024 2 years 2 months |
| Outcome | Defendant Win — Claims Dismissed |
| Patents at Issue | |
| Accused Products | Lidocaine Topical System, 1.8% |
Case Overview
The Parties
⚖️ Plaintiff
A specialty pharmaceutical company commercializing ZTlido®, a non-opioid lidocaine-based topical analgesic system marketed as a targeted pain relief solution.
⚖️ Co-Plaintiff
A Japanese pharmaceutical ingredients and formulation company, likely a licensor or co-developer of the underlying patch technology.
⚖️ Co-Plaintiff
A Japanese specialty chemicals subsidiary of the Itochu conglomerate, suggesting international licensing arrangements in the patent portfolio.
🛡️ Defendant
A Florida-based contract drug delivery manufacturer specializing in transdermal and topical systems.
🛡️ Co-Defendant
U.S. and Canadian arms of one of North America’s largest generic pharmaceutical manufacturers.
Patents at Issue
This case centered on three U.S. patents protecting the lidocaine topical system technology underlying Scilex’s branded ZTlido® (lidocaine topical system, 1.8%) product. These patents collectively cover formulation compositions, adhesive patch systems, and delivery mechanisms associated with the 1.8% lidocaine topical system.
- • US9925264B2 — Covers formulation compositions and adhesive patch systems.
- • US9931403B2 — Directed to adhesive patch systems and delivery mechanisms.
- • US9283174B2 — Relates to delivery mechanisms and 1.8% lidocaine topical system.
Developing a new pharmaceutical product?
Check if your formulation or delivery system might infringe existing patents before launch.
The Verdict & Legal Analysis
Outcome
The court entered **final judgment in favor of Defendant Aveva Drug Delivery Systems, Inc.**, dismissing all claims under Plaintiffs’ Amended Complaint with prejudice. The judgment is explicit: “Plaintiffs shall take nothing from Defendant from this action.” No damages were awarded to Scilex or its co-plaintiffs, and no injunctive relief was granted. This is a complete defense victory on all three asserted patents related to the 1.8% lidocaine topical system.
Key Legal Issues
The court’s ruling was grounded in its Findings of Fact and Conclusions of Law — a comprehensive written opinion suggesting the judge carefully evaluated both factual and legal disputes. While the specific legal basis for the defendant’s victory (non-infringement, invalidity, or both) is contained in that separate order rather than the judgment itself, several strategic and procedural factors illuminate the outcome:
Claim Construction as a Pivotal Factor: In pharmaceutical formulation patent cases involving topical delivery systems, claim construction disputes — particularly around concentration ranges, adhesive composition, and delivery mechanism terminology — frequently determine infringement outcomes.
Multi-Patent, Multi-Defendant Complexity: The defendants’ twelve-attorney legal team from Rakoczy Molino — a firm with deep pharmaceutical patent litigation expertise — suggests a sophisticated, multi-front defense strategy potentially encompassing invalidity challenges (obviousness, anticipation), non-infringement arguments, and possibly inequitable conduct defenses across all three patents simultaneously.
Bench Trial Dynamics: The issuance of separate Findings of Fact and Conclusions of Law is characteristic of a bench trial, meaning Judge Dimitrouleas served as both judge and factfinder. In pharmaceutical patent cases, bench trials allow for nuanced technical analysis without jury instruction complexity, often benefiting defendants with detailed invalidity or non-infringement technical arguments.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical topical delivery. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all related patents in this technology space
- See which companies are most active in topical drug delivery patents
- Understand claim construction patterns for lidocaine formulations
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Topical Lidocaine Formulations (1.8%)
Related Patents
In topical drug delivery systems
Design-Around Options
Possible with nuanced formulation changes
✅ Key Takeaways
Complete defense verdicts across multiple pharmaceutical formulation patents remain achievable with strong claim construction arguments and well-resourced defense teams.
Search related case law →Bench trial format in patent cases demands technically precise expert testimony and detailed written briefing — preparation depth directly shapes Findings of Fact outcomes.
Explore precedents →Frequently Asked Questions
Three U.S. patents: US9925264B2, US9931403B2, and US9283174B2 — all covering lidocaine topical system formulations and delivery technology underlying the ZTlido® 1.8% product.
The court issued separate Findings of Fact and Conclusions of Law supporting a complete judgment for the defendants. The precise legal grounds (non-infringement, invalidity, or both) are detailed in that order. Plaintiffs were awarded no damages or injunctive relief.
The ruling may signal narrowing judicial interpretation of topical drug delivery formulation patent claims, potentially emboldening other generic manufacturers to challenge similar pharmaceutical patch patents.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER — Case No. 0:22-cv-61192
- USPTO Patent Center — US9925264B2, US9931403B2, US9283174B2
- Cornell Legal Information Institute — U.S. Code Title 35
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.